Emerging treatment options for ovarian cancer: focus on rucaparib
Lavanya Mariappan,1 Xue Yan Jiang,1 Josie Jackson,2 Yvette Drew2 1Northern Centre for Cancer Care, Freeman Hospital, 2Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are an exciting class of antican...
Saved in:
Main Authors: | Mariappan L (Author), Jiang XY (Author), Jackson J (Author), Drew Y (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
by: Pearre DC, et al.
Published: (2018) -
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
by: Alfonso Yubero, et al.
Published: (2023) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018) -
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
by: Justin A. Harold, et al.
Published: (2018) -
Emerging Treatment Options for Myelofibrosis: Focus on Anemia
by: Sastow D, et al.
Published: (2023)